PHARMANEXT
ActiveSummary
The computed 12-month bankruptcy probability of PHARMANEXT is 2.1% (moderate). The 2025 annual accounts show equity of €531,183 and a net result of €169,596. Equity is growing by ~32.5% per year across the filed fiscal years. Its solvency ranks better than 34% of 12,456 sector peers (NACE 47, fiscal year 2025). The company has been active since 2018 and the Belgian State Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
26-06
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Highest result since 2019net €169,596 ▲21.6%
Operating result €208,071, net result €169,596, both a record.
31-12
Financial
Equity above €500,000Eq €531,183 ▲20.3%
7 profitable years in a row build equity to €531,183.
27-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
22-10
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 83 days late
2023
01-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 1 day late
2022
31-12
Financial
Equity above €200,000Eq €253,572 ▲40.6%
4 profitable years in a row build equity to €253,572.
13-10
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 74 days late
2021
31-12
Financial
Equity above €150,000Eq €180,386 ▲86.2%
3 profitable years in a row build equity to €180,386.
22-07
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
27-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.